AP
ITOS

Advisors Preferred’s iTeos Therapeutics ITOS Stock Holding History

Advisors Preferred’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-90,973
Closed -$1.69M – 231
2022
Q4 		$1.69M Buy
+90,973
New +$1.78M 0.72% 29

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Advisors Preferred's ITOS Position: Q1 2023 in Review

Advisors Preferred sold out of iTeos Therapeutics (ITOS) in Q1 2023, closing a stake of 90,973 shares — an estimated $1.69M sold.

Advisors Preferred first reported a position in ITOS in Q4 2022 and held it in 1 quarter. The position peaked at $1.69M in Q4 2022. 153 funds tracked by Wall St. Rank hold ITOS as of Q1 2023.

  • Advisors Preferred reported no remaining iTeos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Advisors Preferred sold 90,973 iTeos Therapeutics shares in Q1 2023, an estimated $1.69M.
  • Advisors Preferred first reported a position in iTeos Therapeutics in Q4 2022 and held it in 1 quarter.
  • Advisors Preferred's iTeos Therapeutics position peaked at $1.69M in Q4 2022.
  • 153 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2023.

Based on Advisors Preferred's 13F filing for Q1 2023, filed 3 May 2023.